Paper Details

  1. Home
  2. Paper Details

Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials.

Author: BaslundBo, FaurschouMikkel, GraudalNiels, Hubeck-GraudalThorbjørn, JürgensGesche

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness of standard medications for rheumatoid arthritis (RA) with and without the addition of biologic drugs. Biologic drugs are significantly more expensive, costing about 100 times more than standard medications, but their effectiveness has not been proven to be superior.
Paper Details　
Original Abstract of the Article :
The costs of biologic treatment per patient with rheumatoid arthritis (RA) are approximately 100 times the costs of treatment with a combination of conventional disease-modifying antirheumatic drugs (DMARDs). Despite this, biologic agents have not been proven superior. We compared the effects of com...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/acr.22618

データ提供：米国国立医学図書館（NLM）

A Balancing Act: Evaluating Combination Therapy for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that can significantly impact quality of life. This meta-analysis examines the effectiveness of combination therapies, with and without biologic agents, for managing RA. The researchers investigate whether the use of biologic agents, despite their higher cost, offers a significant advantage over conventional disease-modifying antirheumatic drugs (DMARDs) in combination therapies.

The Cost of Effectiveness: Exploring the Benefits of Biologic Agents in RA Treatment

This meta-analysis, like a camel carefully assessing the most efficient route through a desert, compares the effectiveness of different combination therapies for RA. The study found that while biologic agents are significantly more expensive than conventional DMARDs, they have not been proven superior in treating RA. This raises important questions about the cost-effectiveness of biologic agents and the need for more research to clarify their role in RA management.

Navigating the Desert of RA Treatment: Finding the Right Path

This meta-analysis emphasizes the importance of a personalized approach to RA treatment, considering both cost and effectiveness. It highlights the need for ongoing research to identify the optimal combination therapies for individual patients, striking a balance between cost and effectiveness. Like a camel choosing the best path through a desert, finding the right combination therapy for RA can lead to a more fulfilling and manageable journey for patients.

Dr. Camel's Conclusion

This meta-analysis provides valuable insights into the complex world of RA treatment, highlighting the need for careful consideration of both cost and effectiveness when selecting combination therapies. It serves as a reminder that navigating the desert of RA treatment requires a thoughtful and personalized approach.

Date :
  1. Date Completed 2016-02-10
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

25989246

DOI: Digital Object Identifier

10.1002/acr.22618

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.